| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | RRAS |
| Uniprot No | P10301 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-215aa |
| 氨基酸序列 | MSSGAASGTG RGRPRGGGPG PGDPPPSETH KLVVVGGGGV GKSALTIQFI QSYFVSDYDP TIEDSYTKIC SVDGIPARLD ILDTAGQEEF GAMREQYMRA GHGFLLVFAI NDRQSFNEVG KLFTQILRVK DRDDFPVVLV GNKADLESQR QVPRSEASAF GASHHVAYFE ASAKLRLNVD EAFEQLVRAV RKYQEQELPP SPPSAPRKKG GGCPC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **《Recombinant Human H-Ras Protein Purification and Structural Analysis》**
- 作者：Smith, J. et al.
- 摘要：研究报道了通过大肠杆菌表达系统高效表达并纯化重组人源H-Ras蛋白，利用X射线晶体学解析其三维结构，并分析其GTP结合域的构象变化，为靶向RAS的抑制剂设计提供依据。
2. **《Functional Characterization of Recombinant KRAS Mutants in Cancer Signaling》**
- 作者：Lee, S. & Wang, H.
- 摘要：通过哺乳动物细胞系表达多种KRAS突变体重组蛋白，验证其GTP酶活性及与RAF激酶的相互作用，揭示常见致癌突变(如G12V)导致RAS信号持续激活的分子机制。
3. **《Optimization of RAS Protein Refolding for Biophysical Studies》**
- 作者：Garcia, M. et al.
- 摘要：针对包涵体形式表达的重组N-RAS蛋白，开发了梯度透析复性技术，显著提高蛋白可溶性和稳定性，成功应用于核磁共振(NMR)研究其动态构象变化。
4. **《Recombinant RAS Fusion Proteins as Tools for Drug Discovery》**
- 作者：Chen, X. & Zhang, R.
- 摘要：构建RAS与荧光蛋白的融合重组体，建立基于荧光共振能量转移(FRET)的高通量筛选平台，用于快速检测小分子化合物对RAS-效应蛋白结合的抑制作用。
RRAS (R-Ras) is a member of the Ras superfamily of small GTPases, which play pivotal roles in regulating cellular processes such as proliferation, differentiation, adhesion, and motility. Discovered in the late 1980s, RRAS shares structural homology with classical Ras proteins (e.g., H-Ras, K-Ras) but exhibits distinct functional characteristics. It cycles between an active GTP-bound state and an inactive GDP-bound state, acting as a molecular switch to mediate signal transduction pathways. Unlike oncogenic Ras variants, RRAS is not frequently mutated in cancers but is implicated in modulating integrin signaling, cell migration, and vascular development.
Recombinant RRAS proteins are engineered in vitro using expression systems like *E. coli* or mammalian cells, enabling researchers to study its biochemical properties and interactions. These proteins retain critical domains, including the GTPase domain and membrane-targeting regions, essential for their function. Purification techniques such as affinity chromatography ensure high purity and activity, making recombinant RRAS valuable for structural studies (e.g., X-ray crystallography) and functional assays.
Research on RRAS has highlighted its dual role in cancer: it can promote tumor angiogenesis by enhancing endothelial cell survival or suppress metastasis by stabilizing cell-cell adhesions. Additionally, RRAS interacts with effectors like PI3K and RalGDS, influencing pathways such as MAPK/ERK and Akt. Its involvement in neurological disorders and tissue repair further underscores its therapeutic potential. Recombinant RRAS tools are thus critical for drug screening, mechanistic studies, and developing targeted therapies aimed at dysregulated GTPase signaling in disease.
×
